Annual report
6894.TEDINET S100YDWK
Period2025-04-01 → 2026-03-31
Filed2026-06-18
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.6bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥357m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥336m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥396m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥354m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥387m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥333m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥352m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥396m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥340m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥286m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥356m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥327m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥243m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥340m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥286m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥356m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥5.0bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥5.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥5.2bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.5bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.0bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.0bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.7bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥3.4bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.0bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.2bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥583m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥153m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥399m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥105m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥659m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥598m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥375m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥89m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥24m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥66m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥154m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥159m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥146m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥226m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥72m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥208.9 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥260.19 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥238.99 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥177.53 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥248.75 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,930.63 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,823.85 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,685.76 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,497.84 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,392.34 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 79.9% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.9% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.6% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.3% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 123 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 124 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 128 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 134 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 134 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥2.5bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥2.5bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥2.6bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥347m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥342m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥383m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥357m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥377m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥328m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥342m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥383m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥343m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥276m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥360m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥319m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥241m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥331m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.0bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥5.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥5.1bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.5bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥997m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.1bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.0bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.6bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥3.4bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥201.87 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥263.08 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥232.87 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.86 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥241.58 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥85 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥85 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,895.44 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,800.73 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,658.93 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,484.83 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,385.25 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 79.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.8% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.6% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,393,459 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,393,459 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,393,459 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,393,459 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,393,459 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 122 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 123 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 127 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 133 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 133 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Healthcare Related Productsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥4m |
| Healthcare Related Productsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥8m |
| Healthcare Related Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥627m |
| Healthcare Related Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥627m |
| Healthcare Related Productsreportable segment | segment assets | at 2026-03-31 | ¥461m |
| Healthcare Related Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥18m |
| Optical Applications And Special Customized Productsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥21m |
| Optical Applications And Special Customized Productsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥44m |
| Optical Applications And Special Customized Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.0bn |
| Optical Applications And Special Customized Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.0bn |
| Optical Applications And Special Customized Productsreportable segment | segment assets | at 2026-03-31 | ¥950m |
| Optical Applications And Special Customized Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥329m |
| X Ray Residual Stress Analyzerreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥43m |
| X Ray Residual Stress Analyzerreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥20m |
| X Ray Residual Stress Analyzerreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥893m |
| X Ray Residual Stress Analyzerreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥893m |
| X Ray Residual Stress Analyzerreportable segment | segment assets | at 2026-03-31 | ¥366m |
| X Ray Residual Stress Analyzerreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥347m |
| —segment total | employees | at 2026-03-31 | 107 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥68m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥72m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥658m |
| Healthcare Related Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2m |
| Healthcare Related Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥7m |
| Healthcare Related Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥711m |
| Healthcare Related Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥711m |
| Healthcare Related Productsreportable segment | segment assets | at 2025-03-31 | ¥427m |
| Healthcare Related Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥40m |
| Optical Applications And Special Customized Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥487m |
| Optical Applications And Special Customized Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥23m |
| Optical Applications And Special Customized Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥936m |
| Optical Applications And Special Customized Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥936m |
| Optical Applications And Special Customized Productsreportable segment | segment assets | at 2025-03-31 | ¥1.1bn |
| Optical Applications And Special Customized Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥259m |
| X Ray Residual Stress Analyzerreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥28m |
| X Ray Residual Stress Analyzerreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| X Ray Residual Stress Analyzerreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥839m |
| X Ray Residual Stress Analyzerreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥839m |
| X Ray Residual Stress Analyzerreportable segment | segment assets | at 2025-03-31 | ¥415m |
| X Ray Residual Stress Analyzerreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥363m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥518m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥40m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥662m |
| —segment total | employees | at 2026-03-31 | 106 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,223
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 839457000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 711179000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 935911000 | JPY |
| Net sales | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 2486548000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 363135000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 40296000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 258647000 | JPY |
| Operating income | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 662080000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 415295000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 427193000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 1054380000 | JPY |
| Assets | Prior1YearInstant_TotalOfReportableSegmentsAndOthersMember | 1896869000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 9938000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 6798000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 22858000 | JPY |
| Depreciation segment information | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 39595000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 28123000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 2257000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 487411000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 517792000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 893358000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 626936000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 1032855000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2553150000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 893358000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 626936000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 1032855000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2553150000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 347157000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | -18182000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 328821000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 657796000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 366293000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 460806000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 950063000 | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 1777164000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 20299000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 8239000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02021-000OpticalApplicationsAndSpecialCustomizedProductsReportableSegmentMember | 43872000 | JPY |
| Depreciation segment information | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 72410000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E02021-000XRayResidualStressAnalyzerReportableSegmentMember | 43182000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E02021-000HealthcareRelatedProductsReportableSegmentMember | 3524000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |